Enhancement of carcinogen-induced malignant cell transformation by prostaglandin F2α

Toxicology

Volumn 188, Issue 2-3, 2003, Pages 139-147

  Wölfle, Detlef ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

Cell transformation; Nonsteroidal anti inflammatory drugs; Prostaglandins; Tumor promotion

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3 METHYLCHOLANTHRENE; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; METHYLNITRONITROSOGUANIDINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR PROMOTER;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL ASSAY; CHEMICAL CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0038399036     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(03)00077-5     Document Type: Article

References (43)

1. Adachi T., Nakashima S., Saji S., Nakamura T., Nozawa Y. Roles of prostaglandin production and mitogen-activated protein kinase activation in hepatocyte growth factor-mediated rat hepatocyte proliferation. Hepatology. 21:1995;1668-1674.
2. γ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11:1997;1987-1998.
3. Baek S.J., Kim K., Nixon J.B., Wilson L.C., Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamiliy member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 59:2001;901-908.
4. Carter C.A., Ip M.M., Ip C. A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis. 10:1989;1369-1374.
5. 2 receptor in murine 3T3-L1 cells. Differentiation. 60:1996;203-210.
6. γ, is aberrantly expressed in colonic cancers. Carcinogenesis. 19:1998;49-53.
7. Earashi M., Noguchi M., Kinoshita K., Tanaka M. Effects of eicosanoid synthesis inhibitors on the in vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line. Oncology. 52:1995;150-155.
8. Fürstenberger G., Gross M., Marks F. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinognesis. 10:1989;91-96.
9. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willet W.C., Speizer F.E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:1995;609-614.
10. Goodwin J.S., Ceuppens J. Regulation of immune response by prostaglandins. J. Clin. Immunol. 3:1983;295-314.
11. 2 generation by human keratinocytes: a re-evaluation. Carcinogenesis. 15:1994;141-143.
12. 2α. FEBS J. 297:1992;175-178.
13. Hawcroft G., D'Amico M., Albanese C., Markham A.F., Pestell R.G., Hull M.A. Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis. 23:2002;107-114.
14. Hirota C., Iida M., Aoyagi K., Matsumoto T., Tada S., Yao T., Fujishima M. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer. 78:1996;1660-1665.
15. Hufnagl K., Parzefall W., Marian B., Käfer M., Bukowska K., Schulte-Hermann R., Grasl-Kraupp B. Role of transforming growth factor α and prostaglandins in preferential growth of preneoplastic rat hepatocytes. Carcinogenesis. 22:2001;1247-1256.
16. Kimura M., Osumi S., Ogihara M. Stimulation of DNA synthesis and proliferation by prostaglandins in primary cultures of adult rat hepatocytes. Eur. J. Pharmacol. 404:2000;259-271.
17. Kroll B., Kunz S., Klein T., Schwarz L.R. Effect of lindane and phenobarbital on cyclooxygenase-2 expression and prostanoid synthesis by Kupffer cells. Carcinogenesis. 20:1999;1411-1416.
18. Labayle D., Fischer D., Vielh P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 101:1991;635-639.
19. 2 release in keratinocytes cultures following exposure to various tumour promoters. Toxicol. In Vitro. 9:1995;205-211.
20. Ledwith B.J., Pauley C.J., Wagner L.K., Rokos C.L., Alberts D.W., Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-typ tumor promoters in immortalized mouse liver cells. J. Biol. Chem. 272:1997;3707-3714.
21. Lee P.P.H., Ip M.M. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostagl. Leukotr. Essent. Fatty Acids. 45:1992;21-31.
22. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272:1997;3406-3410.
23. Lupulescu A. Hormonal regulation of epidermal tumor development. J. Invest. Dermatol. 77:1981;186-195.
24. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot. Essent. Fatty Acids. 54:1996;83-94.
25. Marks F., Müller-Decker K., Fürstenberger G. A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology. 153:2000;11-26.
26. Marnett L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
27. Marquardt H., Philips F.S., Sternberg S.S. Tumorigenicity in vivo and induction of malignant transformation and mutagenicity in cell cultures by adriamycin and daunomycin. Cancer Res. 36:1976;2065-2069.
28. 2α receptor mRNA in normal, hyperplastic and neoplastic skin. Carcinogenesis. 21:2000;1063-1066.
29. Müller-Decker K., Scholz F., Marks F., Fürstenberger G. Differential expression of prostaglandin H synthase isozymes during multi-stage carcinogenesis in mouse epidermis. Mol. Carcinog. 12:1995;31-41.
30. 2 inhibitor. Gann. 73:1982;841-843.
31. Parrett M.L., Harris R.E., Joarder F.S., Ross M.S., Clausen K.P., Robertson F.M. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 10:1997;503-507.
32. Reddy B.S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 47:1987;5340-5346.
33. Reginato M.J., Krakow S.L., Bailey S.T., Lazar M.A. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ J. Biol. Chem. 273:1998;1855-1858.
34. Sakata T., Hasegawa R., Johansson S.L., Zenser T.V., Cohen S.M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res. 46:1986;3903-3906.
35. Sanchez J.H., Abernethy D.L., Boreiko C.J. Reversible expression of morphological transformation in C3H 10T1/2 mouse embryo cultures exposed to 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis. 7:1986;1793-1796.
36. 2α) induces cyclin D1 expression and DNA synthesis via early signaling mechanism in Swiss mouse 3T3 cells. Biochem. Biophys. Res. Commun. 270:2000;11-16.
37. 2α receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem. Biophys. Res. Commun. 233:1997;200-202.
38. Sessler A., Ntambi J.M. Polyunsaturated fatty acid regulation of gene expression. J. Nutr. 128:1998;923-926.
39. Tsubouchi Y., Sano H., Kawahito Y., Mukai S., Yamada R., Kohno M., Inoue K., Hla T., Kondo M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem. Biophys. Res. Commun. 270:2000;400-405.
40. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83:1995;493-501.
41. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-148.
42. Wölfle D., Marotzki S., Dartsch D., Schäfer W., Marquardt H. Induction of cyclooxygenase expression and enhancement of malignant cell transformation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Carcinogenesis. 21:2000;15-21.
43. 2 in ornithine decarboxylase induction by a tumor-promoting agent, 7-bromomethylbenz[a]anthracene, in mouse epidermis. Carcinogenesis. 13:1992;905-906.